Dual and Triple Agonists Transform MASLD Therapy by Targeting Multiple Incretin and Metabolic Pathways
From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease.
Abstract
Dual and triple agonists like Tirzepatide and Retatrutide are transforming MASLD therapy, achieving significant reductions in liver fat and body weight via multi-incretin targeting.
